Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SuPERIOR: Neoadjuvant NORT and Durvalumab in Locally Advanced NSCLC
NCT06191250Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by University Health Network. Primary endpoint: CD8+ Tumor-Infiltrating Lymphocytes density at 17 days. Started Sep 2024; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06191250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191250.